D. Osborne
Director of Finance/CFO at Melt Pharmaceuticals, Inc.
Profile
D.
Bradford Osborne is currently the Chief Financial Officer at Melt Pharmaceuticals, Inc. Prior to this, he worked at Precigen, Inc. as the Principal Accounting Officer & VP-Finance from 2011 to 2021.
D. Osborne active positions
| Companies | Position | Start |
|---|---|---|
Melt Pharmaceuticals, Inc.
 Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Director of Finance/CFO | 31/01/2022 |
Former positions of D. Osborne
| Companies | Position | End |
|---|---|---|
| PRECIGEN, INC. | Director of Finance/CFO | 09/06/2021 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PRECIGEN, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Health Technology |
- Stock Market
- Insiders
- D. Osborne
